 MyoKardia NASDAQ: MYOK soared 96 this week after reporting its investigational heart drug met primary and all secondary endpoints in a phase 3 clinical trial. The clinical stage biotech company will submit mavacamten for the treatment of obstructive hypertrophic cardiomyopathy HCM to the U.S. Food and Drug Administration FDA for review early next year. MyoKardia has four other treatments for serious cardiovascular diseases in the pipeline, but mavacamten, as its most advanced candidate, likely will be the main catalyst for share movement for a while to come. 